Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.

In the RB-CHOP arm ( Fig 2C ), the results in the MHG group showed a nonsignificant trend toward improvement (3-year PFS rate, 58%), which provides possible evidence of a positive effect of bortezomib despite the small number of patients ( P = .08 Fig 2E ).

also in 5,406 other papers